⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31175398 | 0.51 | — | — | |
| SCHEMBL29612863 | 0.38 | — | — | |
| SCHEMBL151342 | 0.38 | — | — | |
| SCHEMBL9615101 | 0.38 | — | — | |
| SCHEMBL5119978 | 0.38 | — | — | |
| Charcoal, Activated SCHEMBL5440419 | 0.38 | — | — | |
| SCHEMBL31414726 | 0.38 | — | — | |
| SCHEMBL5383540 | 0.38 | — | — | |
| Potassium Ion SCHEMBL261973 | 0.38 | — | — | |
| Zinc Ion SCHEMBL11122846 | 0.38 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362334-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362341-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9764039-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9738724-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9732161-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170096463-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9517273-B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3076377-A1 | METHOD FOR PROVIDING INFORMATION ABOUT FREE SPACE IN A REGION SURROUNDING A MOTOR VEHICLE AS RAW SENSOR DATA AT A COMMUNICATION INTERFACE, SENSOR DEVICE, PROCESSING DEVICE AND MOTOR VEHICLE | Valeo Schalter und Sensoren GmbH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20140194357-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8735539-B2 | Relaxin polypeptides comprising non-naturally encoded amino acids | AMBRX, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140011740-A1 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES | ELI LILLY COMPANY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569233-B2 | Modified animal erythropoietin polypeptides and their uses | ELI LILLY AND COMPANY (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130237474-A1 | Biosynthetic Polypeptide Fusion Inhibitors | AMBRX, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237481-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. | 2013-09-12 | — | — | US | disclosed |
| US-20130150564-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |